Stonnington Group LLC decreased its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 37.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,424 shares of the biopharmaceutical company’s stock after selling 46,028 during the period. Pfizer comprises about 1.0% of Stonnington Group LLC’s, making the stock its 26th largest holding. Stonnington Group LLC’s holdings in Pfizer were worth $4,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently modified their holdings of the business. New World Advisors LLC bought a new stake in shares of Pfizer during the third quarter worth about $292,000. EagleClaw Capital Management LLC grew its holdings in Pfizer by 2.1% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 29,959 shares of the biopharmaceutical company’s stock worth $1,287,000 after acquiring an additional 625 shares during the last quarter. Dark Forest Capital Management LP increased its position in Pfizer by 8.5% in the 3rd quarter. Dark Forest Capital Management LP now owns 3,186 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 250 shares during the period. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the third quarter valued at $38,000. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Pfizer by 1,161.8% during the third quarter. Voloridge Investment Management LLC now owns 117,017 shares of the biopharmaceutical company’s stock worth $5,033,000 after purchasing an additional 107,743 shares during the period. Hedge funds and other institutional investors own 66.50% of the company’s stock.
In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the transaction, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $1,907,300. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jennifer B. Damico sold 4,218 shares of the company’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the sale, the senior vice president now owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock worth $2,075,003 in the last 90 days. 0.05% of the stock is currently owned by company insiders.
Shares of Pfizer stock opened at $50.09 on Friday. The stock has a market capitalization of $281.05 billion, a PE ratio of 11.49, a price-to-earnings-growth ratio of 0.58 and a beta of 0.76. Pfizer Inc. has a 52 week low of $38.82 and a 52 week high of $61.71. The stock has a 50 day moving average price of $50.51 and a two-hundred day moving average price of $52.21. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. During the same period in the previous year, the business posted $0.93 EPS. The business’s revenue for the quarter was up 76.8% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 6.61 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.19%. Pfizer’s payout ratio is presently 36.70%.
PFE has been the topic of a number of analyst reports. Citigroup upped their price target on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research report on Tuesday, April 5th. The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a research report on Wednesday, May 25th. SVB Leerink assumed coverage on shares of Pfizer in a research note on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price objective on the stock. Morgan Stanley assumed coverage on shares of Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.26.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.